BioCentury | Feb 22, 2016

Investing upstream

...right side of what seemed like a likely disruptive innovation," said Kolchinsky. T2 markets its T2Candida Panel...
BioCentury | Dec 5, 2015
Financial News

Portola, T2 raise follow-ons

...launched its T2Candida Panel and T2Dx instrument to detect Candida pathogens that lead to sepsis. The T2Candida panel...
BioCentury | Mar 23, 2015
Analyst Picks & Changes

Analyst picks & changes

...buying opportunity as the company's risk/reward profile has increased since FDA's September approval of the T2Candida Panel...
BioCentury | Oct 6, 2014

3Q14 Stock Wrap-Up: Going big again treat relapsed or refractory peripheral T-cell lymphoma (PTCL) T2 Biosystems Inc. (NASDAQ:TTOO) FDA approves T2Candida Panel...
BioCentury | Oct 6, 2014
Clinical News

T2Candida Panel regulatory update

...FDA approved T2 Biosystems' T2Candida Panel and T2Dx Instrument to detect and identify 5 species of Candida...
...would not be cleared via the 510(k) pathway. T2 Biosystems Inc. (NASDAQ:TTOO), Lexington, Mass. Product: T2Candida Panel...
BioCentury | Sep 24, 2014
Company News

T2 gains on approval of fungal tests

...Biosystems Inc. (NASDAQ:TTOO) jumped $1.62 (10%) to $18.55 on Tuesday after FDA approved the company's T2Candida Panel...
BioCentury | Jun 9, 2014
Clinical News

T2Candida assay regulatory update detect the sepsis-causing pathogens. T2 Biosystems Inc. , Lexington, Mass. Product: T2Candida assay ( Candida test...
BioCentury | Sep 16, 2013
Clinical News

T2Candida assay: Pivotal trial started

...NMR-based molecular and immunodiagnostic platform. T2 Biosystems Inc. , Lexington, Mass. Product: T2Candida assay ( Candida test...
BioCentury | Aug 22, 2011
Product Development

Nano-NMR for diagnostics

...series D round this month to support an FDA submission for its first product, a Candida test... approved, according to McDonough. "Infectious disease societies have understood the importance of having a Candida test...
BioCentury | Aug 11, 2011
Financial News

T2 raises $23M in series D

Diagnostic company T2 Biosystems Inc. (Lexington, Mass.) raised $23 million in a series D round led by new investor Aisling Capital. Existing investors Flagship Ventures; Polaris Venture Partners; Flybridge Capital Partners; Physic Ventures; Partners Healthcare;...
Items per page:
1 - 10 of 11